Texas Tech Chemist to Study Cell Death with $520,000 NIH Grant
September 22, 2010
New method could lead to better treatments for cancer, heart disease.
A chemistry researcher at Texas Tech University received a $520,000 grant to find
better methods of studying cell death that could lead to more useful medications for
ailments such as heart disease and cancer.
Dimitri Pappas, an assistant professor in the Department of Chemistry and Biochemistry,
received the three-year grant to study how the body kills off cells and how that knowledge
may be used to develop new treatments.
Known as apoptosis, it’s the body’s natural way of selectively killing off cells to
balance cell growth. But when it’s out of balance, Pappas said, it can lead to serious
“When it goes haywire, you can have rapid cell growth that leads to cancer, or rapid
cell death that leads to atrophy,” Pappas said.
Currently, ways to measure apoptosis are time-consuming and limit scientists’ understanding
of how it might be manipulated, he said. Pappas will use the grant to discover new
methods to rapidly measure the rate of death in a number of cells.
The hope, he said, is to use the new methods in conjunction with medicines that offer
more effective treatments. For example, chemotherapy kills cancer cells, but also
kills many normal cells during the treatment. The new method could lead to the discovery
of more targeted drugs that help speed up cell death in cancer cells rather than healthy
Or, it could help develop a drug that could stop rapid cell death in patients with
heart disease, he said.
“What this will realistically enable us to do is to test new drug compounds that will
allow or prohibit apoptosis,” he said. “We’ll be able to weed out candidates faster.”
CONTACT: Dimitri Pappas, assistant professor, Department of Chemistry and Biochemistry,
Texas Tech University, (806) 742-3142, or email@example.com